Hepatic fibrosis 2022: Unmet needs and a blueprint for the future
Scott L. Friedman, Massimo Pinzani – 18 December 2021 – Steady progress over four decades toward understanding the pathogenesis and clinical consequences of hepatic fibrosis has led to the expectation of effective antifibrotic drugs, yet none has been approved. Thus, an assessment of the field is timely, to clarify priorities and accelerate progress. Here, we highlight the successes to date but, more importantly, identify gaps and unmet needs, both experimentally and clinically.